Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS



Date/App# patent app List of recent Mammal-related patents
08/20/15
20150234886 
 System and  selection of data according to measurement of physiological parameters patent thumbnailSystem and selection of data according to measurement of physiological parameters
It is one object of the present invention to disclose a method for filtering targeted data comprising steps of: a. Providing a plurality of m devices di; each of the di is adapted to measure a physiological parameter; b.
Beyond Verbal Communication Ltd


08/20/15
20150233941 
 Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection patent thumbnailSubstances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. The method for screening an allograft recipient (including pregnant women) for chronic allograft rejection comprises the steps of measuring an amount of a natural antibody within a biological sample and comparing the amount of the first natural antibody with the amount of the first natural antibody present within a control sample; wherein a decrease in the amount of the first natural antibody as compared to those levels seen in the control indicates a diagnosis of being at-risk for or experiencing chronic allograft rejection.
3dt Holdings, Llc


08/20/15
20150233920 
 Antibody for skewing sex ratio and methods of use thereof patent thumbnailAntibody for skewing sex ratio and methods of use thereof
A purified antibody, or an antigen-binding fragment thereof, is provided that binds selectively to a protein specific to an x-chromosome of a mammalian sperm cell. The sperm cell protein comprises an amino acid sequence set forth in seq id nos: 4 and 9-16.
University Of Tennessee Research Foundation


08/20/15
20150232941 
 Method of diagnosing cancer comprising detection of the methylation signature in the htert promoter patent thumbnailMethod of diagnosing cancer comprising detection of the methylation signature in the htert promoter
A method of diagnosing cancer in a mammal is provided. The method includes the steps of determining in a nucleic acid-containing sample from the mammal the degree of dna methylation of a target region within the htert promoter from the nucleotide at about position −157 to the nucleotide at about position −580, or a corresponding target region in a tert promoter in a mammal other than a human, to yield a sample methylation signature, determining the baseline degree of dna methylation of the target region in a control sample to yield a control methylation signature, comparing the sample methylation signature to the control methylation signature and rendering a diagnosis of cancer when there is at least 1.5 times more methylation in the sample methylation signature as compared to the control methylation signature.
The Hospital For Sick Children


08/20/15
20150232933 
 Methods for evaluating pathologic conditions using extracellular rna patent thumbnailMethods for evaluating pathologic conditions using extracellular rna
This invention provides methods for the detection, diagnosing, monitoring, or predicting of non-neoplastic diseases, pathologic conditions, and injury. The methods of the invention detect extracellular non-neoplastic mammalian rna in the blood, blood plasma, serum, cerebrospinal fluid or other bodily fluid of an animal, most preferably a human, having or predisposed to having a non-neoplastic disease, pathologic condition, or injury..

08/20/15
20150232879 
 Conditional expression of transgenes in vivo patent thumbnailConditional expression of transgenes in vivo
The present invention relates to a method of producing a cell comprising a conditionally active transgene in its genome, the method comprising (a) introducing into the cell a targeting vector, wherein the targeting vector comprises (i) a 5′ recombinase recognition site specifically recognised by a first recombinase, wherein the first recombinase is endogenously present in the cell or wherein the first recombinase or a nucleic acid molecule encoding said first recombinase in expressible form is introduced into the cell; followed by (ii) a 5′ recombinase recognition site specifically recognised by a second recombinase, wherein the second recombinase is not endogenously present or is not active in the cell; followed by (iii) a selection cassette comprising a positively selectable marker gene; followed by (iv) a 3′ recombinase recognition site specifically recognised by a third recombinase, wherein the third recombinase is not endogenously present or is not active in the cell; followed by (v) the transgene; followed by (vi) a 3′ recombinase recognition site specifically recognised by a fourth recombinase, wherein the fourth recombinase is endogenously present in the cell or wherein the fourth recombinase or a nucleic acid molecule encoding said fourth recombinase in expressible form is introduced into the cell; wherein the genome of the cell comprises a 5′ recombinase recognition site and a 3′ recombinase recognition site that are identical to the recombinase recognition sites of (i) and (vi), and wherein said recombinase recognition sites comprised in the genome of the cell are located 3′ of an endogenous cellular promoter such that introduction of the targeting vector into the genome by site specific recombination results in the promoter being operatively linked to the selectable marker gene; and (b) culturing the cell in the presence of a selection medium specific for the selectable marker encoded by the selectable marker gene of (iii). The present invention further relates to a method of producing a conditional transgenic non-human mammalian animal as well as to a conditional transgenic non-human mammalian animal obtainable by said method.
Helmholtz Zentrum MÜnchen-deutsches Forschungszentrum FÜr Gesundheit Und


08/20/15
20150232857 
 Oligonucleotide-containing pharmacological compositions and their use patent thumbnailOligonucleotide-containing pharmacological compositions and their use
The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.. .
Lakewood-amedex, Inc.


08/20/15
20150232808 
 Methods of reprogramming animal somatic cells patent thumbnailMethods of reprogramming animal somatic cells
This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease..
Advanced Cell Technology, Inc.


08/20/15
20150232807 
 Method for isolation and purification of epithelial stem cells from skin patent thumbnailMethod for isolation and purification of epithelial stem cells from skin
The current invention concerns a method for obtaining a cellular composition comprising epithelial stem cells (epscs) from mammalian skin, whereby said composition comprises at least 90% of viable epscs, comprising the steps of:—obtaining a mammalian skin sample;—obtaining a cell suspension from said skin sample by performing at least one enzymatic dissociation step; and—culturing said cell suspension under low-attachment conditions. Preferably cellular composition comprises epithelial stem cells derived from the epidermal layer.
Pell Cell Medicals Nv


08/20/15
20150232564 
 Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor patent thumbnailRegulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
A method of reducing il-4 and/or il-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of il-3, il-5 and gm-csf to the βc common chain to thereby reduce the il-4 and/or il-13 levels.. .
Newcastle Innovation Ltd.


08/20/15
20150232536 

Igg stimulated remyelination of peripheral nerves


The present invention is based on the discovery of polyclonal igg's ability to promote schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal igg are provided.
Baxter Healthcare Sa


08/20/15
20150232528 

High-efficiency, sodium -specific, blue-shifted channelrhodopsins


Methods and compositions used to identify and characterize a new channelrhodopsin derived from algae which is highly efficient, sodium specific and blue-shifted. The rhodopsin domain of this channelrhodopsin can be cloned and expressed in mammalian systems and thus used in optogenetic applications and as therapeutic agents..
Board Of Regents Of The University Of Texas System


08/20/15
20150232513 

Compositions and methods for treating hepatitis b


The present invention provides compositions and methods for treating hepatitis b virus (hbv) infection as well as methods for identifying a compound or a composition that is suitable for treating hbv infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit hbv replication or treat hbv infection in a mammal.
The Regents Of The University Of Colorado, A Body Corporate


08/20/15
20150231374 

Intravascular catheters, systems, and methods


Devices, systems, and methods for lead delivery. In at least one exemplary embodiment of a catheter for delivering a lead within a mammalian body of the present disclosure, the catheter comprises an elongated tube comprising a wall extending from a proximal end to a distal end, a lead delivery channel within the elongated tube, the lead delivery channel defining an outlet for delivering a lead, a balloon chamber positioned at or near the distal end of the elongated tube, and at least one balloon positioned within the balloon chamber, the at least one balloon capable of inflation to reversibly anchor the elongated tube within a mammalian body when at least a portion of the elongated tube is positioned therein..
Cvdevices, Llc


08/20/15
20150231317 

Cannula tip for use with a vad


The present invention includes various embodiments of methods of circulating blood in a mammalian circulatory system, and various blood circulation assemblies adapted to perform such circulation. In one embodiment of the present invention, a blood circulation assembly includes a blood circulation device having an inlet and a discharge; a first cannula including a proximal portion in communication with the inlet, the proximal portion having a wall extending around a first longitudinal axis and having outer and inner faces, said inner face defining a bore, and a distal portion including an outer face tapering distally toward said axis and at least two openings extending from said outer face and merging with one another to form a hollow space within said distal portion, said hollow space communicating with said bore of said proximal portion; and a second cannula including a proximal portion in communication with the discharge, the proximal portion having a wall extending around a first longitudinal axis and having outer and inner faces, said inner face defining a bore, and a distal portion including an outer face tapering distally toward said axis and at least two openings extending from said outer face and merging with one another to form a hollow space within said distal portion, said hollow space communicating with said bore of said proximal portion..
Heartware, Inc.


08/20/15
20150231276 

Role of dh44 and homologs in calorie sensing


Provided are methods for identifying drosophila melanogaster mutants which have mutations affecting calorie sensing behavior. Also provided are methods for identifying agents that can interfere with calorie sensing behavior in d.
New York University


08/20/15
20150231232 

Outer membrane vesicles


The present invention provides an outer membrane vesicle (omv) from a gram-negative bacterium, comprising at least one heterologous protein that is free in the lumen of the omv, wherein the omv is capable of eliciting an immune response to the heterologous protein when administered to a mammal. The invention also provides methods for preparing the omvs of the invention, pharmaceutical compositions comprising the omvs of the invention, especially immunogenic compositions and vaccines, and methods of generating an antibody immune response in a mammal using omvs..
Novartis Ag


08/20/15
20150231209 

Stimulation of ovarian follicle development and oocyte maturation


Methods are provided for stimulating ovarian follicles in a mammal through disruption of the hippo signaling pathway.. .
The Board Of Trustees Of The Leland Stanford Junior University


08/20/15
20150231188 

Medical food for fetal health during gestation


Medical foods that create fertility enhancement also improve the health of a fetus or child. Multiple examples demonstrate this in mammals.
Cortcontrol


08/20/15
20150231173 

Methods for treating skin irritation


The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solutions, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, and treating skin irritations, among other uses..
Puricore, Inc.


08/20/15
20150231168 

Methods for sustained and regulatable gene expression using viral based expression vectors


Disclosed are genetic expression cassettes, and vectors comprising them useful for the delivery of isolated nucleic acid segments including those expressing or encoding one or more selected therapeutic constructs (including, without limitation, therapeutic peptides, polypeptides, ribozymes, or catalytic rna molecules), to one or more selected cells or tissues of a vertebrate animal. Methods employing the disclosed genetic constructs in the development of gene therapy-based viral vector systems are also disclosed.
University Of Florida Research Foundation, Inc.


08/20/15
20150231123 

Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level


The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders.
Pharnext


08/20/15
20150230933 

Facet joint replacement


A prosthesis for the replacement of at least a portion of the bone of a facet located on a mammalian vertebra, comprising: an articulating surface that articulates with another facet; a bone contacting surface that contacts a surface of the vertebra, the articulating surface being connected to the bone contacting surface; and a fixation element that attaches the bone contacting surface to the vertebra, the fixation element being adapted for implantation into an interior bone space of a pedicle of the vertebra; wherein the prosthesis is configured so that no portion of the prosthesis contacts the posterior arch of the vertebra.. .
Gmedelaware 2 Llc


08/20/15
20150230821 

Heat pipe cooled burr including surgical instruments embodying same


Featured is a surgical instrument including a rotating cutting implement and a heat transfer mechanism configured to absorb heat energy during the use of such a rotating cutting implement. The heat transfer mechanism is configured so the absorbed heat energy is communicated to an external heat sink.
Gyrus Acmi, Inc. (d.b.a. Olympus Surgical Technolo


08/20/15
20150230730 

Pulmonary plethysmography based on optical shape sensing


The present invention relates a pulmonary plethysmographic system (10), the system with a garment (11) wearable on the body of a mammal, e.g. A human, the garment comprising a shape sensing fiber (12) with a plurality of optical fibers (30) to facilitate optical measurements of strain along the length of the shape sensing fiber.
Koninklijke Philips N.v.


08/20/15
20150230430 

Veterinary composition and methods for non-surgical neutering and castration


A method for non-surgical neutering or castration of a non-human mammal for aav-mediated delivery of an anti-gnrh polypeptide to a non-human animal is described. More particularly, the animal is administered an adeno-associated virus (aav) vector having an aav capsid having packaged therein nucleic acid sequences comprising an aav 5′ inverted terminal repeat (itr), a sequence encoding a polypeptide which specifically binds gonadotropin releasing hormone (gnrh) under control of regulatory sequences which direct expression of the polypeptide, and an aav 3′ itr.
The Trustees Of The University Of Pennsylvania


08/13/15
20150225740 

Importation of mitochodrial protein by an enhanced allotopic approach


An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)


08/13/15
20150225723 

Gene nanocomposite, and cellular internalization gene using same


A gene nanocomposite and a cellular internalization method of a gene using the same are provided. More specifically provided is a gene nanocomposite including: a photosensitizer-conjugated polymer; and one or more materials selected from a gene and a gene/cationic polymer composite, and a cellular internalization method of a gene using the same to improve gene delivery efficiency into a mammal-derived cell and gene expression..
Catholic University Of Korea Industry-academy Cooperation Foundation


08/13/15
20150225698 

In vitro pancreatic differentiation of pluripotent mammalian cells


This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (de) medium comprising a tgfp ligand, fibroblast growth factor (fgf), bone morphogenetic protein (bmp), a pi3k inhibitor and optionally a gsk3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; fgf; retinoic acid; and a bmp inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising fgf, retinoic acid, a bmp inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising fgf. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells.
Cambridge Enterprise Limited


08/13/15
20150225333 

Crystalline solid and amorphous forms of (-)-halofenate and methods related thereto


The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to type 2 diabetes and hyperlipidemia.
Diatex, Inc.


08/13/15
20150224233 

Cross-linked fatty acid-based biomaterials


Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents.
Atrium Medical Corporation


08/13/15
20150224213 

Treatment of neurological disorders


This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering rna (irna) agent capable of decreasing expression of a target rna associated with the neurological disorder.
Medtronic, Inc.


08/13/15
20150224189 

Silicon dioxide nanoparticles and the use thereof for vaccination


The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer.
Merck Patent Gmbh


08/13/15
20150224149 

Composition for parenteral administration, producing and method use thereof


The present invention relates to a field of veterinary and human medicine. In particular, the invention relates to a composition suitable for parenteral administration, based on hydrolyzate obtained from natural bioresources, a composition for use in treating and/or preventing a pathological condition in a mammal in need thereof, and various other uses thereof.

08/13/15
20150224135 

Biocidal polymers


Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(c1-c6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.. .
Wisconsin Alumni Research Foundation


08/13/15
20150224124 

Reducing the reproductive capacity of mammals


Provided are compositions and methods for reducing the reproductive capacity of mammals. The compositions and methods involve the use and administration of (a) a diterpenoid epoxide comprising a triptolide skeleton and which causes ovarian follicle depletion in female mammals and (b) an organic diepoxide which causes ovarian follicle depletion in female mammals..
Senestech, Inc.


08/13/15
20150224066 

Antimicrobial compositions and methods of use


The disclosure relates to antibiotic compositions and methods of use thereof in a mammal. In certain embodiments, the present invention provides an antimicrobial composition comprising a non-aqueous carrier and an active agent, wherein the active agent is menadione, 1,4-naphthoquinone, coenzyme q1, coenzyme q2, coenzyme q3, coenzyme q4, coenzyme q5, coenzyme q6, coenzyme q7, coenzyme q8, coenzyme q9, and/or coenzyme q10, or a pharmaceutically acceptable salt thereof..
University Of Iowa Research Foundation


08/13/15
20150224025 

Therapeutic substance and acupressure system


According to one embodiment, a system includes an acupressure device configured to apply pressure to one or more pressure points on a mammal. The system further includes a therapeutic substance coupled to the acupressure device..

08/06/15
20150219628 

Methods for detecting and monitoring endocrine disrupting chemicals (edcs)


Described herein are compositions, methods, a system, and kits for detection of endocrine disruptor chemicals (edcs) in samples, such as samples of water including but not limited to waste water treatment plant effluent, using a live-cell fluorescence-based nuclear translocation reporter system. Upon binding of a ligand to a fluorescent-labeled reporter protein, the protein (and therefore the fluorescence) is translocated in a ligand level-dependent manner from the cytoplasm to the nucleus of live mammalian cells; this translocation is detectable as diffuse (cytoplasmic) fluorescence converting to localized, brightly fluorescent nuclei.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


08/06/15
20150219622 

Methods, systems and compositions for functional in vitro cellular models of mammalian systems


The present invention comprises methods, systems and compositions comprising cell culture analog systems, comprising components which optionally comprise biologically functional cells, and the components and systems function similarly to in vivo conditions.. .
University Of Central Florida Research Foundation, Inc.


08/06/15
20150218644 

Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer


The invention discloses high levels of receptors for clostridium perfringens enterotoxin (cpe) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of cpe is disclosed.
Yale University


08/06/15
20150218610 

Protein production method


This invention relates to a method for producing a protein of interest, comprising introducing a protein expression vector which comprises a gene fragment a gene fragment comprising a dna encoding a protein of interest and a selectable marker gene and transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell to obtain a mammalian cell capable of expressing the protein of interest; and suspension-culturing the mammalian cell; and a suspension mammalian cell capable of expressing the protein of interest.. .
Inter-university Research-institute Corporation Research Organization Of Information & Systems


08/06/15
20150218584 

Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences


The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5′ of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus. In particular embodiments, the chimeric promoter regulatory sequence comprises sequence elements derived from the murine or the human cytomegalovirus ie1 promoter and from the human and/or the simian cytomegalovirus ie1 region.
Lonza Biologics Plc.


08/06/15
20150218511 

Method for non-freeze low-temperature preservation of mammalian embryo or fertilized egg


Disclosed is a novel means which enables satisfactory preservation of embryos and fertilized eggs in the non-frozen state for a longer period than conventional means, which novel means also achieves high hatching ability and a high conception rate of the embryos after the preservation. The method for preserving a mammalian embryo(s) or fertilized egg(s) of the present invention comprises immersing a mammalian embryo(s) or fertilized egg(s) in a medium containing 20 to 80% (v/v) serum and 10 to 100 mm good's buffer, and storing the embryo(s) or fertilized egg(s) at non-freezing low temperature.
National Federation Of Agricultural Cooperative Associations


08/06/15
20150218247 

Taci as an anti-tumor agent


A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a taci reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the taci reagent.. .
Biogen Idec Ma Inc.


08/06/15
20150218236 

Immunomodulatory proteins


A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an fc receptor binding portion comprising two immunoglobulin g heavy chain constant regions; wherein each immunoglobulin g heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin g heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.. .
Liverpool School Of Tropical Medicine


08/06/15
20150218207 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


08/06/15
20150218103 

Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness


The present invention provides compounds and composition comprising analogs of deprenyl and their use in the inhibition of nuclear gapdh-siahl binding and the activation of p300 and mef2. Also provided herein are methods of prevention and treatment of stress induced disorders of the body, including, for example, major mental illness, such as schizophrenia, mood disorders, and addiction, as well as stress-associated diseases involving other organs, such as cardiac hypertrophy, in vivo, comprising administering to a mammal a therapeutically effective amount of analogs of deprenyl..
Showa Pharmaceutical University


08/06/15
20150218098 

Prolyl hydroxylase inhibitors


Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (hif-1α), as well as hypoxia inducible factor-2 (hif-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds.
Aerpio Therapeutics Inc.


08/06/15
20150218090 

Dosage regimen for an s1p receptor modulator or agonist


This invention relates to a method of treating multiple sclerosis in a mammalian patient, preferably a human, in need of such treatment, comprising administering to said human an s1p receptor modulator or agonist according to a dosing regimen that is determined with reference to the patient's blood lymphocyte count.. .
Novartis Ag


08/06/15
20150217120 

Neuromodulation systems and methods of using same


Neuromodulation systems are described. An example neuromodulation system includes a controller wirelessly communicatively coupled to a host computer, a signal generator communicatively coupled to the controller, and a plurality of electrodes communicatively coupled to the signal generator.

08/06/15
20150217002 

Near-infrared spectroscopy and optical reporter


The method of the present disclosure is directed towards a method for determining the concentration of an analyte in a mammal's bloodstream. This method includes the following steps; applying a patch to the mammal's skin, the patch configured to transmit a reporter through the mammal's skin, wherein the reporter is configured to have an affinity for the analyte and is capable of exhibiting a detectable change in fluorescence upon binding to the analyte, subjecting a portion of the mammal's skin to near infrared spectroscopy (nirs), detecting fluorescence emission intensity and calculating the concentration of the analyte based on the detected fluorescence emission.
The Research Foundation For The State University Of New York


08/06/15
20150216957 

Placental vaccination therapy for cancer


The present invention discloses methods of stimulating an immune response to cancer tissue and biological effectors used by tumors to defeat the host, through the immunization of a mammal using placental tissue, cells, molecules, and combinations thereof. In one embodiment, the invention provides the utilization of syngeneic, allogeneic, xenogeneic, and combinations thereof as immunizing sources..

08/06/15
20150216923 

Biochemical scaffolds for modulating cell function


A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a krebs cycle modulator, glutathione modulator, neurotransmitter modulator and a dna modulator, the vibrational platform comprising a plurality of herbs that are subjected to harmonic oscillation in the range of approximately 102 ghz-250 ghz for a period of time in the range of approximately 3-5 hrs.. .

08/06/15
20150216887 

Compositions for oral administration to animals, production methods thereof and uses of same


The invention relates to a method for the production of a time-stable, solid appetising composition and to the use thereof, said composition comprising at least one active substance which is introduced in the final production step, by adding same to the already formed mixture of other components at ambient temperature, without the use of water or heat. The composition is intended for use as a drug, a nutraceutical or a food supplement for oral administration to mammals, except humans, in particular for pets such as dogs, cats or horses.
Friulchem Spa


08/06/15
20150216718 

Devices, thermoelectric heating and cooling of mammalian tissue


Provided are devices for heating, cooling, or maintaining temperature of mammalian tissue. Also provided are methods for using the same.
Board Of Regents, The University Of Texas System


08/06/15
20150216588 

Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction


Methods and apparatus are provided for selective destruction or temporary disruption of nerves and/or conduction pathways in a mammalian body for the treatment of pain and other disorders. Apparatus comprises catheters having electrodes for targeting and affecting nerve tissue at a cellular level to reversible and irreversible nerve poration and incapacitation..
Medtronic Ardian Luxembourg S.a.r.l.


08/06/15
20150216471 

Diagnostic device and sensing hydration state of a mammalian subject


Detection of one or more fronts of saliva advancing simultaneously in multiple directions may be used to determine salivary secretion rate, as may be indicative of state of euhydration or dehydration. An array of electrical contacts may be arranged between a substrate and a liquid collection element, and used to detect saliva migrating through the liquid collection element.
Hydradx Inc.


08/06/15
20150216181 

Pesticide having an insecticide, acaricide and nematicide action based on isoquinoline alkaloids and flavonoids


The present invention relates to a pesticide having an insecticide, acaricide and nematicide action obtained from plant extracts that have important synergic interactions in their pesticide activity, the characteristics of which are efficient control of insects, mites and nematodes; low toxicity for mammals and low persistence in the environment. This pesticide is a composition based on plant extracts which is characterized because it is constituted by: isoquinoline alkaloids and their derivatives (0.1-20%) and flavonoids and their glycosylated derivatives (0.001-10%).
Promotora Tecnica Industrial, S.a. De C.v.


07/30/15
20150215127 

Method of secure communication utilizing a cryptographic neural implant for reception of visual system signals


A method for the secure communication of sensitive information in which the receiver of the sensitive information is equipped with a neural implant capable of stimulating the visual system of a mammalian brain. In this method, a transmitting party encrypts an image or a sequence of images and sends them to a computational device or devices securely connected to the receiving party's neural implant.
Neurocryptonics Innovations L.l.c.


07/30/15
20150212084 

Specific removal of activated immune cells


The present invention provides a method of detecting an immune response in a mammalian subject by: (a) withdrawing blood or a blood fraction containing immune cells from the subject; (b) contacting the blood or blood fraction to an antibody (e.g., a monoclonal antibody) that specifically binds to the cell surface hla-f histocompatibility protein of activated mammalian immune cells, which antibody does not bind to the cell surface of non-activated mammalian immune cells; and then (c) detecting the presence or absence of binding of the immune cells to the antibody, the presence of binding indicating the presence of an immune response in the subject. A further aspect of the invention is a composition comprising, consisting of or consisting essentially of a solid support having an antibody (e.g., a monoclonal antibody) coupled thereto, which antibody specifically binds to the cell surface hla-f histocompatibility protein of activated mammalian t-lymphocytes, and which antibody does not bind to the—cell surface of non-activated mammalian t-lymphocytes.
The Fred Hutchinson Cancer Research Center


07/30/15
20150211020 

Complex chromosome engineering for production of human antibodies in transgenic animals


The invention relates to large-scale production of human antibodies by transgenic animals with high production of fully human igg up to >10 g/l in sera with human igg1 subclass dominancy. This invention also supports a feasibility of complex chromosome engineering for complicated genetic studies in non-murine mammalian species..
Sab, Llc


07/30/15
20150210992 

Method for production of recombinant human alpha-galactosidase a


Disclosed is a method for production of recombinant human alpha-galactosidase a (rh alpha-gal a) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-gal a-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, and (g) to gel filtration column chromatography, in the order..
Jcr Pharmaceuticals Co., Ltd.


07/30/15
20150210985 

Generation of patient-specific differentiated cell types by epigenetic induction


Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line.

07/30/15
20150210983 

Maintenance and propagation of mesenchymal stem cells


Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated stale in the absence of feeder cells and applications of the same.. .
The United States Of America As Represented By The Department Of Veterans Affairs


07/30/15
20150210980 

System for in-situ management of ph of culture


Disclosed is a hydrogel composition loaded with a base that regulates and maintains the ph of cell culture media. The invention particularly discloses in situ ph managing hydrogels (phmh) loaded with base mg(oh)2 for ph control in small scale cultures comprising adherent mammalian cells, suspended mammalian cells, microorganisms, a microorganism with plasmids and the like thereof..
Council Of Scientific & Industrial Research


07/30/15
20150210727 

Compounds and methods for treating mammalian gastrointestinal microbial infections


Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of impdh. In certain embodiments, a compound selectively inhibits a parasitic impdh versus a host impdh.
The Brigham And Women's Hospital, Inc.


07/30/15
20150210626 

Cycloalkyl-diamines


The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal, especially a human, in need of such treatment a compound of formula i as described above, and a method of treatment of a disorder or condition selected from the group consisting human african trypanosomiasis (hat), chagas disease, malaria, leishmaniasis, and other infectious diseases transmitted to humans and animals by exposure to parasites, the method comprising administering to a human or mammal in need of such treatment a compound of formula i as described above.. .

07/30/15
20150209482 

Cross-linked fatty acid-based biomaterials


Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents.
Atrium Medical Corporation


07/30/15
20150209478 

Articles for tissue regeneration with biodegradable polymer


The invention is to articles made from extracellular matrix sheets that encase biodegradable polymeric material. Methods of healing wounds or regenerating tissue at sites of defect by placing said articles in mammals are claimed.
Cormatrix Cardiovascular, Inc.


07/30/15
20150209441 

Anandamide-modified nucleic acid molecules


The present invention refers to a conjugate comprising at least one polyunsaturated fatty acid residue, particularly an arachidonic acid residue, more particularly an anandamide (arachidonoyl ethanol amide) residue and covalently bound thereto at least one nucleosidic component selected from nucleic acids, nucleosides and nucleotides. This conjugate is suitable for the transfection of cells such as mammalian cells including human cells with high efficacy.
Baseclick Gmbh


07/30/15
20150209435 

Aqueous drug delivery system


Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof..
Bev-rx, Inc.


07/30/15
20150209409 

Uses of il-12 in hematopoiesis


Methods for enhancing or stimulating hematopoiesis including the step of administering interleukin-12 (il-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering il-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state.
University Of Southern California


07/30/15
20150209407 

Methods for the treatment and prevention of osteoporosis and bone-related diseases


The present disclosure is directed to the identification that r-spondin-1 (rspo1) acts as a positive regulator of bone formation. Accordingly, the presently disclosed subject matter provides methods for treating and/or preventing osteoporosis or bone-related disorders, including administering a pharmaceutical composition of a therapeutically effective amount of an r-spondin (rspo) agonist, e.g., an rspo protein or functional fragment thereof, peptidomimetic, nucleic acid, small molecule, or other drug candidate, to a subject, e.g., a mammal.
The Trustees Of The University Of Pennsylvania


07/30/15
20150209401 

Synergistic multi-active composition for topical treatment of disorders in mammals, use of composition, and method


A synergistic composition comprising two substrates, active against many diseases of mammals, particularly humans. The substrates are particularly extracts of the aroeira plant (myracroduon urundeuva) and of the alecrim-pimenta plant (lippia sidoides)..

07/30/15
20150209339 

Hetero-substituted acetanilide derivatives as analgesic agents


Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever..
Janssen Pharmaceutica N.v


07/30/15
20150209280 

Fatty acid pharmaceutical foam


The present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a fatty acid. The composition may further comprise a pharmaceutically active agent.
Stiefel Research Australia Pty Ltd


07/30/15
20150209176 

Medical device for the treatment of hemorrhoids, tissue inflammation and other conditions


This invention is directed to a medical device and a method of treating mammals, especially humans, to alleviate the symptoms, including pain, of several conditions and symptoms, including hemorrhoids, tissue inflammation and/or yeast infections, and open, draining wounds or incisions.. .

07/23/15
20150204856 

Methods to determine fluid filtration rates through mammalian luminal organs


Methods to determine fluid filtration rates through mammalian luminal organs. In one method, the method comprises the steps of positioning a segment of a mammalian luminal organ within a device, the device configured to prevent axial flow conditions through a lumen of the segment from a first end of the segment to an opposite second end of the segment, obtaining a first segment measurement at a first time, obtaining a second segment measurement at a second time, and determining a rate of fluid filtration through a wall of the segment based upon a difference between the first segment measurement and the second segment measurement and a difference in time between the first time and the second time..
Dtherapeutics, Llc


07/23/15
20150203890 

Production of sialylated n-glycans in lower eukaryotes


The present invention relates to eukaryotic host cells which have been modified to produce sialylated glycoproteins by the heterologous expression of a set of glycosyltransferases, including sialyltransferase and/or trans-sialidase, to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. Novel eukaryotic host cells expressing a cmp-sialic acid biosynthetic pathway for the production of sialylated glycoproteins are also provided.
Glycofi, Inc.


07/23/15
20150203851 

Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer


A method of treating autoimmune and inflammatory diseases or conditions or cancer in a mammal, such as a human, which comprises the administration of an inhibitor of the bromodomain-containing protein pcaf.. .
Glaxo Group Limited


07/23/15
20150203821 

Immortalized stem cell, compositions, preparations and uses thereof


The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose of the present invention is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant.
Quarrymen Corporation


07/23/15
20150203811 

Sperm cell separation methods and compositions containing aptamers or nucleic acid sequences for use therein


The present invention provides an aptamer or pool of aptamers (nucleic acid sequences) that bind(s) to a target molecule on the surface, accessible from the surface or inside of a mammalian sperm cell and a method for producing the aptamers. The method comprises contacting a collection of different nucleic acid molecules with the target molecule under conditions favorable for binding between at least one of the nucleic acid molecules and the target molecule, to form at least one complex comprising the nucleic acid molecule bound to the target molecule, wherein each of the nucleic acid molecules comprises at least one segment of randomized nucleotide sequences.
Biocern, Inc.


07/23/15
20150203541 

Flagellin related polypeptides and uses thereof


The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.. .
Cleveland Clinic Foundation


07/23/15
20150203502 

Pyrrolopyrimidine and purine derivatives


Or pharmaceutically acceptable salts thereof, wherein q, t, v, w, x, y, z, ring a, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals.

07/23/15
20150203455 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202651 

Recombinant spider silk protein film and synthesizing


Methods for forming useful films using recombinant spider silk protein are discussed. In one embodiment, the method involves dissolving silk protein in a sufficient quantity to form a film suspended in a solvent.
Utah State University


07/23/15
20150202458 

Laser therapy for at least one of grade iii and grade iv capsular contracture


A method for treating at least one of grade iii capsular contracture and grade iv capsular contracture in a mammalian subject includes positioning a laser device proximate to the subject. The method also includes applying low level near infrared radiation to an area of the subject proximate to tissue in the subject experiencing at least one of grade iii capsular contracture and grade iv capsular contracture for treating the capsular contracture..
Riancorp Pty Ltd.


07/23/15
20150202427 

Device for augmenting blood flow, tissue perfusion and fluid distribution by neuromuscular stimulation in horses and other non-human mammals


The invention relates to a method and device for neuromuscular stimulation of one or more muscles, or muscle groups, with one or more beneficial effects selected from increasing arterial, venous and capillary blood flow, increasing flux of interstitial fluid and lymphatic drainage, increasing tissue oxygenation, enhancing heat distribution, enhancing the distribution of pharmaceutical products, and enhancing performance and recovery from exertion in horses.. .
Sky Medical Technology Ltd.


07/23/15
20150202408 

Medical device and delivery method onto offset surface of mammal tissue


A novel medical device and method for delivery of a scaffold for treatment of secondary lymphedema and ischemia is provided. In some embodiments a catheter medical device and magnetic guidance method are provided for delivering cell-seeded implants for guided lymphatic regeneration..
Fibralign Corporation


07/23/15
20150202401 

Conversion of nitrogen dioxide (no2) to nitric oxide (no)


A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal..
Geno Llc


07/23/15
20150202303 

2-iminobiotin formulations and uses thereof


The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the disclosure pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from that administration..
Neurophyxia B.v.


07/23/15
20150202278 

Method of using attenuated bordetella strains


A mutated bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampg gene is provided. The attenuated mutated bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a bordetella infection.
Institut National De La Sante Et De La Recherche Medicale (inserm)


07/23/15
20150202237 

Halobacteria extracts composition for tumor reduction


A composition and method for treating solid tumors in a mammalian subject. The composition includes halobacterial extracts and dunaliella extracts, containing antioxidants.
Dr. Nona International Ltd


07/23/15
20150202218 

Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections


Disclosed are methods of treating, inhibiting, or preventing a viral infection in a mammal in need thereof by administering a therapeutically or prophylactically effective amount of an inhibitor of fap, an inhibitor of dppiv, an inhibitor of dpp8, or an inhibitor of dpp9. The inhibitor may act as both an inhibitor of dppiv and an inhibitor of dpp8/9.
Trustees Of Tufts College


07/23/15
20150202214 

Combination of regorafenib and acetylsalicylic acid for treating cancer


The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.. .
Bayer Ag


07/23/15
20150202180 

Pharmaceutical compositions of anisomelic acid and the use thereof


A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of anisomelic acid or salts thereof. The pharmaceutical composition may comprise anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.

07/23/15
20150202178 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

07/23/15
20150202176 

Compositions for prevention/prophylactic treatment of poison ivy dermatitis


Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the anacardiaceae and ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.. .

07/23/15
20150202164 

Oral rapamycin nanoparticle preparations


Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders.

07/23/15
20150202063 

Graft devices and related systems and methods


In some aspects, graft devices for a mammalian patient can include a tubular member comprising a first end; and a fiber matrix surrounding the tubular member, wherein the fiber matrix is designed and constructed to be substantially continuously tapered at the first end to define a diameter that increases as it approaches the first end.. .
Neograft Technologies, Inc.




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5261

4807

2 - 1 - 114